OncoMatch/Clinical Trials/NCT06660420
Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)
Is NCT06660420 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Cyclophosphamide and Fludarabine for phase 1.
Treatment: Cyclophosphamide · Fludarabine — To find the highest tolerable dose and recommended dose of PRAME-TCR-NK cells that can be given to participants with recurrent and/or refractory melanoma. The safety and tolerability of PRAME-TCR-NK cells will also be studied.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Melanoma
Biomarker criteria
Required: HLA-A A*02:01
Participants must have HLA A*02:01
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: immune checkpoint inhibitor (anti-PD-1, anti-CTLA-4, anti-LAG-3) — metastatic
relapsed and/or refractory to immune checkpoint inhibitor (ICI) therapy including either anti-PD-1 either with or without anti-CTLA-4 blocking antibody and/or anti-LAG-3 antibody
Lab requirements
Cardiac function
left ventricular ejection fraction >50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06660420 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received immune checkpoint inhibitor.
Does this trial require HLA-A?
Yes, HLA-A A*02:01 is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages